Is Viking Therapeutics, Inc. (VKTX) a Buy, Sell, or Hold?
Viking Therapeutics, Inc.
NASDAQ:VKTX
$37.97 USD
-$0.15 (-0.39%)
- Volume
- 1.34M
- Average Volume
- 2.44M
- Market Capitalization
- $4.41B
- P/E Ratio
- -9.17
- Dividend Yield
- 0.00%
- Price Target
- $95.00
- Year High
- $43.15
- Year Low
- $22.96
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $5.72
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Brian Lian |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | VKTX |
| CUSIP | 92686J106 |
| CIK | 0001607678 |
| Web | https://www.vikingtherapeutics.com |
| Phone | 858 704 4660 |
| Currency | USD |
| Employees | 59 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.00 |
| Payout Ratio | 0.00 |
| Current Ratio | 5.72 |
| Quick Ratio | 5.72 |
| Cash Ratio | 1.11 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -2.94 |
| Price / Cash Flow | -12.95 |
| Price / Book | 8.74 |
Price Target and Rating
| Average Stock Price Forecast | $95.00 |
| High Stock Price Forecast | $101.00 |
| Low Stock Price Forecast | $83.00 |
| Forecast Upside/Downside | -60.03% |
| Consensus Rating | Strong Sell |
| Rating Score(0-5) | 1 |
| Research Coverage | 24 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-3.19 |
| Trailing P/E Ratio | -9.17 |
| PEG Ratio | 0.11 |
| P/E Growth | 0.11 |
| Net Income | $-359.64M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -71.31% |
| Return on Assets | -77.66% |
Financials Score
| AltmanZ Score | 21.09 |
| Piotroski Score | 1.00 |
| Working Capital | 501.88M |
| Total Assets | 608.24M |
| Ebit | -472.3M |
| Market Cap | 4.43B |
| Total Liabilities | 106.32M |
Poll Results
About Viking Therapeutics, Inc. (NASDAQ:VKTX) Stock
Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß). This compound is currently progressing through Phase IIb clinical trials, targeting both non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients and non-alcoholic fatty liver disease (NAFLD). Viking's pipeline also features VK5211, an oral, non-steroidal selective androgen receptor modulator undergoing Phase II studies for individuals recuperating from non-elective hip fracture surgery. Additionally, VK0612, an oral drug candidate for type 2 diabetes, is ... poised to enter Phase IIb trials. The firm is also developing VK0214, another orally active, tissue and receptor-selective TRß agonist, specifically aimed at X-linked adrenoleukodystrophy. Founded in 2012, Viking Therapeutics is headquartered in San Diego, California.
Viking Therapeutics, Inc. (VKTX) Stock Falls Amid Market Uptick: What Investors Need to Know
2026-07-10 18:46:10
Viking Therapeutics, Inc. (VKTX) reached $38.86 at the closing of the latest trading day, reflecting a -5.54% change compared to its last close.
Viking Therapeutics: Still Cheap, But Watch Double Top
2026-07-10 11:50:47
Viking Therapeutics is advancing its GLP-1 weight-loss pipeline, with Phase 3 trials progressing and oral formulation development accelerating. The consensus analyst price targets average $92.58, suggesting substantial upside. Recent biotech sector M&A highlights VKTX's potential valuation in a rapidly expanding GLP-1 market.
Viking Therapeutics (VKTX) Price Forecast: Bottoming Pattern Signals Growing Strength
2026-07-09 17:34:29
Viking Therapeutics continues to strengthen within a long-term bottoming pattern, but a pullback or decisive breakout above major resistance will likely determine the next trend.
Is This Biotech Stock a Buy After Its Massive Rally?
2026-07-09 15:00:00
Viking Therapeutics (VKTX +2.28%) may be one of biotech's most tempting buyout targets, thanks to its weight loss drug pipeline and massive obesity market opportunity. But the stock also carries serious risk, especially as a better-funded rival gains a head start.
Buyout Buzz Around VKTX Is Back: What's Fueling the Speculation?
2026-07-09 11:01:20
Viking Therapeutics' expanding obesity pipeline and upcoming VK2735 data reignite buyout speculation as investors weigh its growing strategic appeal.
3 High Growth GLP-1 Biotech Winners to Buy in July
2026-07-09 08:00:59
The GLP-1 trade has matured from a single-stock story into a tiered opportunity set.
Why Viking Therapeutics, Inc. (VKTX) Dipped More Than Broader Market Today
2026-07-08 18:51:14
Viking Therapeutics, Inc. (VKTX) closed the most recent trading day at $39.97, moving 5.13% from the previous trading session.
Chip Rout Drags Nasdaq 100 Lower, Oil Climbs: Stock Market Today
2026-07-07 13:20:32
A deepening sell-off in chip and memory stocks dragged all four major U.S. equity indexes lower by midday Tuesday.
Frequently Asked Questions
-
What is the current Viking Therapeutics, Inc. (VKTX) stock price?
-
Viking Therapeutics, Inc.(NASDAQ:VKTX) stock price is $37.97 in the last trading session. During the trading session, VKTX stock reached the peak price of $43.15 while $22.959 was the lowest point it dropped to. The percentage change in VKTX stock occurred in the recent session was --0.39% while the dollar amount for the price change in VKTX stock was -$-0.15.
-
VKTX's industry and sector of operation?
-
The NASDAQ listed VKTX is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of VKTX?
-
Hubert C. Chen | Chief Medical Officer
Neil Aubuchon | Chief Commercial Officer
Geoffrey E. Barker | Chief Development Officer
Nils U. Olsson | Senior Vice President of Technical Operations
Gregory S. Zante | Chief Financial Officer -
How many employees does VKTX have?
-
Number of VKTX employees currently stands at 59. VKTX operates from 9920 Pacific Heights Boulevard, San Diego, CA 92121, US.
-
Link for VKTX official website?
-
Official Website of VKTX is: https://www.vikingtherapeutics.com
-
How do I contact VKTX?
-
VKTX could be contacted at phone #858 704 4660 and can also be accessed through its website. VKTX operates from 9920 Pacific Heights Boulevard, San Diego, CA 92121, US.
-
How many shares of VKTX are traded daily?
-
The average number of VKTX shares traded daily for last 3 months was 2.44M.
-
What is the market cap of VKTX currently?
-
The market value of VKTX currently stands at $4.41B with its latest stock price at $37.97